Lipoflex Special Without Electrolytes (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The formulation provides a balanced blend of essential amino acids that act as direct substrates for protein synthesis. By delivering these building blocks into the bloodstream, the solution bypasses the gastrointestinal tract, allowing rapid incorporation into cellular proteins, supporting metabolic processes, and preventing catabolism in patients who are unable to ingest food.

The dose of Lipoflex Special Without Electrolytes is individualized by the prescribing clinician based on the patient’s weight, clinical condition, and nutritional requirements. Healthcare professionals calculate the appropriate infusion rate and total daily amino‑acid provision to meet specific metabolic goals.

Safety data in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Lipoflex Special Without Electrolytes is formulated without added electrolytes, which can simplify compatibility with other intravenous medications. Compared with some branded alternatives that include electrolytes, it may reduce the need for additional electrolyte monitoring, but clinicians must still assess the patient’s overall electrolyte status and supplement as required.

The product must be stored at 2‑8 °C, protected from light, and should not be frozen or shaken. Before use, inspect the container for any signs of contamination or precipitation, and allow the solution to reach room temperature if required for infusion.

It is administered intravenously, typically via a controlled infusion pump. The infusion rate is set according to the prescribed daily amino‑acid dose, and the solution is delivered through a dedicated line or compatible IV set, with regular monitoring of infusion parameters and patient response.

Serious risks include anaphylactic reactions, metabolic acidosis, and severe hyperammonemia, especially in patients with underlying liver disease or inborn errors of metabolism. Prompt recognition of symptoms such as hypotension, respiratory distress, or altered mental status is essential, and immediate medical intervention should be initiated.

Patients with known hypersensitivity to any of the amino‑acid components, those with specific inborn errors of amino‑acid metabolism (e.g., phenylketonuria), or individuals with uncontrolled severe hepatic or renal failure where amino‑acid overload could be harmful should not be given this product unless a specialist determines it is appropriate.